title: A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease.
abstract: The objective of this position statement from the Saudi Gastroenterology Association is to guide gastroenterologists on the use of tumor necrosis factor-alfa (TNF-α) antagonists for the treatment of the idiopathic inflammatory bowel diseases, Crohn's disease, and ulcerative colitis. In this article, we summarize the relevant literature regarding the safety and efficacy of TNF-α antagonists, highlight relevant safety concerns specific to the environment in Saudi Arabia, and provide specific recommendations for the use of these agents.
authors.affiliation: Department of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Medicine, University of Western Ontario, London, Ontario, Canada, .
authors.forename: Mahmoud H
authors.initials: MH
authors.lastname: Mosli
authors.forename: Othman
authors.initials: O
authors.lastname: Al-Harbi
authors.forename: Brian G
authors.initials: BG
authors.lastname: Feagan
authors.forename: Majid A
authors.initials: MA
authors.lastname: Almadi
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000068582:Certolizumab Pegol / Q000627:therapeutic use; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab / Q000627:therapeutic use; D012529:Saudi Arabia; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; C529000:golimumab; D000069285:Infliximab; D000068879:Adalimumab; D000068582:Certolizumab Pegol